Trending NewsTrending NewsNASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $2.88 -0.04 (-1.37%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.91 +0.03 (+0.90%) As of 08/8/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About biote Stock (NASDAQ:BTMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get biote alerts:Sign Up Key Stats Today's Range$2.87▼$3.0450-Day Range$2.88▼$4.5552-Week Range$2.87▼$6.98Volume239,176 shsAverage Volume133,724 shsMarket Capitalization$157.56 millionP/E Ratio3.20Dividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company Overview biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas. Read More biote Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreBTMD MarketRank™: biote scored higher than 52% of companies evaluated by MarketBeat, and ranked 442nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus Ratingbiote has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst Coveragebiote has only been the subject of 1 research reports in the past 90 days.Read more about biote's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-28.00% Earnings GrowthEarnings for biote are expected to decrease by -28.00% in the coming year, from $0.75 to $0.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 3.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.91.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 3.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.95. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.90% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in biote has recently decreased by 2.23%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.90% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in biote has recently decreased by 2.23%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment-0.01 News Sentimentbiote has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for biote this week, compared to 2 articles on an average week.Search Interest2 people have searched for BTMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, biote insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address BTMD Stock News HeadlinesB. Riley Issues Negative Estimate for biote EarningsAugust 9 at 2:57 AM | americanbankingnews.combiote Corp. (NASDAQ:BTMD) Q2 2025 Earnings Call TranscriptAugust 8 at 9:27 AM | msn.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 9 at 2:00 AM | Brownstone Research (Ad)B. Riley Securities Downgrades biote (BTMD)August 8 at 4:26 AM | msn.combiote Corp. (BTMD) Q2 2025 Earnings Call TranscriptAugust 7 at 4:00 AM | seekingalpha.comBiote Reports Second Quarter 2025 Financial ResultsAugust 6 at 4:05 PM | businesswire.comBiote Schedules Second Quarter 2025 Financial Results Release and Conference CallJuly 23, 2025 | businesswire.comBiote Names Rich Barrera to Board of DirectorsJune 9, 2025 | businesswire.comSee More Headlines BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $6.18 at the beginning of the year. Since then, BTMD shares have decreased by 53.4% and is now trading at $2.88. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) issued its earnings results on Wednesday, August, 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. The firm had revenue of $48.86 million for the quarter, compared to analysts' expectations of $49.52 million. biote had a net margin of 15.73% and a negative trailing twelve-month return on equity of 19.71%. Read the conference call transcript. Who are biote's major shareholders? Top institutional shareholders of biote include Acadian Asset Management LLC (1.25%), Geode Capital Management LLC (1.13%), Los Angeles Capital Management LLC (0.37%) and Connor Clark & Lunn Investment Management Ltd. (0.03%). Insiders that own company stock include Guines Llc, Roystone Capital Management Lp, Stephen Mark Cone, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of biote own? Based on aggregate information from My MarketBeat watchlists, some other companies that biote investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings8/06/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Price Target for biote$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+108.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio3.20 Forward P/E Ratio3.84 P/E GrowthN/ANet Income$3.16 million Net Margins15.73% Pretax Margin10.93% Return on Equity-19.71% Return on Assets17.83% Debt Debt-to-Equity RatioN/A Current Ratio1.42 Quick Ratio1.14 Sales & Book Value Annual Sales$197.19 million Price / Sales0.80 Cash Flow$0.76 per share Price / Cash Flow3.81 Book Value($2.78) per share Price / Book-1.04Miscellaneous Outstanding Shares54,710,000Free Float41,580,000Market Cap$157.56 million OptionableNot Optionable Beta1.21 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BTMD) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.